// App-Quantinova.ai

TPS352 : A phase IIb, open-label, single-arm study of zanidatamab (ZW25) monotherapy in subjects with advanced or metastatic HER2-amplified biliary tract cancers.

Researchers

Presenter

  • Shubham Pant

Principal Investigators

  • Michel Ducreux

  • James J. Harding

  • Milind M. Javle

  • Do-Youn Oh

  • Harpreet Singh Wasan

  • Allison Fortenberry

  • Neil C. Josephson

  • Anthony Mwatha

  • Kui Wang

  • Jia Fan

Medical Centers

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • Gustave Roussy Cancer Campus, Villejuif, France

  • Department of Surgery, Gynecologic Service, Memorial Sloan-Kettering Cancer Center, New York, NY

  • Hammersmith Hospital, Division of Cancer, Imperial College London, London, United Kingdom

  • Zymeworks Incorporated, Vancouver, BC, Canada

  • Seattle Genetics, Bothell, WA

  • Zymeworks, Seattle, WA

  • BeiGene Co., Ltd., Shanghai, China

  • Department of Liver Surgery and Transplantation, Zhongshan Hospital and Liver Cancer Institute, Fudan University, Shanghai, China

Locations

  • United States

  • France

  • Republic of South Korea

  • United Kingdom

  • Canada

  • China

Companies

  • Zymeworks Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Advanced biliary tract carcinoma

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • Gemcitabine

  • ZW25

Outcome

  • N/A

Study Design

  • Open Label

  • Single Arm

  • Multicenteric

Phase

  • II

Study Id's

  • NCT02892123

  • NCT04466891

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved